Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

NCT00660881 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

BIOLOGICAL: Epratuzumab

Sponsor

UCB Pharma